Revolution Medicines

Director, US Strategic Pricing, Pipeline

Redwood City, California, United States · Director · Full-time

Sponsorship not specified$211k-$264kDetected 22 hours ago

ComplianceForecastingLeadershipCommunicationCollaborationPublic Speaking

About the role

Ensure compliance with all applicable laws, regulations, and company policies related to pricing and contracting.
The Director, US Strategic Pricing will serve as a subject matter expert in US Market Access and Oncology price strategy with deep knowledge of mandated and commercial payer environments, US pricing policy and global pricing interdependences.
The Director will report to the Senior Director, US Strategic Pricing and will serve in a critical function to shape list and net pricing recommendations and strategies as the company grows as a commercial organization.

Develop and lead life cycle list and net price recommendations for pipeline portfolio and indication sequencing pricing strategies.
Effectively partner with internal stakeholders to develop relationships to drive price strategy access including Global Market Access, Pricing, and Development, US Market Access Marketing, Field Key Account teams.
Monitor, assess and recommend pricing adjustments to support life cycle management efforts consistent with pipeline indication expansion opportunities.
Develop contract strategies and structures in close collaboration with USMA, brand and legal partners.
6+ years pricing, and payer/provider contracting experience to support mandated and discretionary price strategies.
Extensive experience and demonstrated success in customer segment contract strategy, market knowledge, and pricing policies to support products and/or portfolio.

Bachelor's degree.
Minimum of 8 years of pharmaceutical market access experience.
2+ years of Oncology product experience.
Strong understanding relationship within IRA policy guidelines and CMS price demonstrations.
Experience with day-to-day management of vendor partners.
Strong knowledge of trends, issues and policies influencing drug pricing and oncology market.
Ability to communicate effectively, both orally and in writing.
Ability to effectively resolve conflicts and multi-department alignment to delivery commercial goals and objectives.
Experience with oral oncology therapies and targeted treatments for RAS-mutated cancers.
Advanced degree (MBA, MPH, or similar).
#LI-Hybrid #LI-SS2
The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below.

$211,000 - $264,000 USD
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process.

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers.
The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.
The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

This listing is sourced directly from Revolution Medicines's careers page and normalized into a canonical job model.